(“Cyprotex” or “the Company”)
Cyprotex launch Short Time Exposure service for identifying potential serious eye damage for new chemicals
Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announce the launch of a new in vitro testing service, the Short Time Exposure (STE) assay for identifying potential serious eye damage from new chemicals. Cyprotex has validated and demonstrated proficiency in the assay based on the draft OECD (Organisation for Economic Co-operation and Development) test guideline released in June 2014.
A complete ban on animal testing of all new cosmetics and their ingredients sold in Europe was put into force in March 2013. In addition, the Classification, Labelling and Packaging (CLP) Regulation, the GHS (Global Harmonised System of Classification and Labelling of Chemicals) and the REACH Regulation all propose the use of in vitro alternative methods for toxicity testing. The STE method has been developed as an in vitro (non-animal) alternative to the animal-based rabbit eye test and Cyprotex are able to perform the service under GLP (Good Laboratory Practice) in order to meet the requirements of these regulatory bodies.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer said, “The addition of the new STE service enables Cyprotex to test chemicals for potentially harmful ocular effects. By bringing this on board we comply with new regulatory guidance and are well placed to meet the needs of our customers for non-animal alternative testing.”
For Further Information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.